Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
9 Meters Biopharma, Inc. NMTR
$0.75
-$0.01 (-1.07%)
На 18:02, 12 мая 2023
+5 233.33%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
10178844.00000000
-
week52high
13.20
-
week52low
0.69
-
Revenue
0
-
P/E TTM
0
-
Beta
1.34775000
-
EPS
-2.74000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 11:00
Описание компании
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Hold | Buy | 01 июл 2022 г. |
| Truist Securities | Buy | Buy | 22 июн 2022 г. |
| BMO Capital | Outperform | Outperform | 22 июн 2022 г. |
| BMO Capital | Outperform | 08 июл 2021 г. | |
| Citigroup | Buy | 04 июн 2021 г. | |
| Oppenheimer | Outperform | Outperform | 27 сент 2022 г. |
| BMO Capital | Outperform | Outperform | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Temperato John | A | 1427522 | 125000 | 06 июл 2022 г. |
| Sirgo Mark A | A | 1560428 | 175000 | 01 июл 2022 г. |
| Sirgo Mark A | A | 1454045 | 175000 | 01 июл 2022 г. |
| Constantino Michael T. | A | 142509 | 142509 | 22 июн 2022 г. |
| JOHNSON LORIN K | A | 142509 | 142509 | 22 июн 2022 г. |
| RICE YEHUDA MICHAEL | A | 142509 | 142509 | 22 июн 2022 г. |
| Ventimiglia Samantha | A | 142509 | 142509 | 22 июн 2022 г. |
| Sirgo Mark A | A | 142509 | 142509 | 22 июн 2022 г. |
| Constantino Michael T. | A | 60509 | 16000 | 23 мая 2022 г. |
| Temperato John | A | 1302522 | 50000 | 18 мая 2022 г. |
Новостная лента
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
Accesswire
31 янв 2023 г. в 08:00
RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters is scheduled to present on Monday, February 6, 2023, at 10:00 AM ET as part of the BIO CEO & Investor Conference being held in New York City. The presentation, which is accessible to registered conference attendees, will highlight the Company's pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome, as well as upcoming milestones.
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Accesswire
18 окт 2022 г. в 08:00
RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced two poster presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting taking place in Charlotte, North Carolina on October 21-26, 2022. The posters highlight preclinical data investigating the use of humanized monoclonal antibodies (hu-mAbs) to glucose-dependent insulinotropic polypeptide (GIP).
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate
Zacks Investment Research
27 сент 2022 г. в 14:17
9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.
How to Find Trending Penny Stocks in 2022
PennyStocks
04 июл 2022 г. в 14:00
Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What to Know About Buying Penny Stocks on June 24th
PennyStocks
24 июн 2022 г. в 07:00
Here's what you need to know about trading penny stocks on June 24th The post What to Know About Buying Penny Stocks on June 24th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.